Pricing Log in Create free account
Saturday 7 November 2026 Export SNDX’s income statement to Excel — free account

Syndax Pharmaceuticals, Inc.

SNDX Healthcare Biotechnology

Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.

Revenue
+81.6%
EPS
+21.4%
Free cash flow
+61.4%
Total debt
+71.1%

Quarter to September 2026, against a year earlier

9.54 0.17 +1.81%
Market cap
$843.6M
P/E
0.0×
Fwd P/E
−6.7×
Dividend yield
—
F-score
n/a
Altman Z
−2.09
Beneish M
3.29
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.86
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 4 — — — 3 1 — — 1 —
Insider Ownership 8.88%

Capital & Financial Ratios $m

Size
Market Cap 843.57
Revenue ttm 289.43
Net income ttm (209.48)
Free cash flow ttm (177.59)
Net debt Q 151.03
Valuation
P/E 0.00
Forward P/E (6.70) (negative: loss-making)
Price / sales 2.96
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 4.69 (at or above 1.5: strong)
Debt / equity Q (34.24) (negative: negative equity)
Interest coverage Q (3.23)
Growth
Revenue growth Q +81.59% (above 0%: growing)
Operating income growth Q +27.05% (above 0%: growing)
EPS, this year +34.69% (at or above 15%: strong)
EPS, next year A +54.24% (at or above 15%: strong)
Revenue, next year A +82.24% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +71.79% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 21.6×; over the ten years it ranged from −63.3× in 2016 to 594× in 2021.
P/S against its own 10 years 0.07%
10-year low 10-year high
EV/Sales against its own 10 years 2.84%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 578 583 414 437
Receivables — 11 68 77
Inventory — 0 33 39
Other — — — —
581 603 528 567
2023 2024 2025 Q'26
Payables 10 12 17 4
ST’ Debt — 12 — —
Other — — — —
58 104 120 121

Compound Annual Growth %

10y 5y 3y
Sales — 157.68% 384.33%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.31%) (23.84%) (48.29%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.52 Actual −0.55

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.64 −0.78 Miss by 0.14
Q1 FY26 −0.59 −0.48 Beat by 0.11
Q2 FY26 −0.45 −0.55 Miss by 0.10
Q3 FY26 −0.52 −0.55 Miss by 0.03
Q4 FY26 −0.52 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.48) (0.55) (0.55) — —
’25 (0.98) (0.83) (0.70) (0.78) (3.29)
’24 (0.85) (0.80) (0.98) (1.10) (3.72)
’23 (0.59) (0.64) (0.73) (1.00) (2.98)
’22 (0.63) (0.62) (0.58) (0.62) (2.46)
’21 (0.54) (0.44) (0.40) 1.81 0.48
’20 (0.56) (0.42) (0.46) (0.44) (1.87)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 65 73 83 — —
’25 20 38 46 68 172
’24 — 4 13 8 24
’21 0 0 12 127 140
’20 0 0 0 0 2
’19 0 0 0 0 2
’18 0 0 0 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (30) (27) — —
’25 (95) (88) (71) (69) (323)
’24 (84) (72) (62) (57) (275)
’23 (39) (35) (45) (41) (161)
’22 (42) (40) (29) (23) (134)
’21 (23) (24) (25) 101 29
’20 (16) (21) (18) (16) (71)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (50) (30) (27) — —
’25 (95) (88) (71) (70) (323)
’24 (84) (72) (62) (57) (275)
’23 (39) (35) (45) (41) (161)
’22 (42) (205) (28) (23) (133)
’21 (23) (151) (25) 101 29
’20 (16) (21) (18) (16) (71)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 2 2 2 2 140 — — 24 172 289 +73.3% 314 459 638 +54.7%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 0.00 — 96.51 95.96 92.21 (4.0) pt
EBT (44) (61) (74) (56) (73) 25 (149) (209) (319) (285) (209) +22.9%
EBT margin, % (3,645.25) (2,884.35) (4,875.48) (3,694.59) (4,822.54) 17.84 0.00 0.00 (1,346.11) (165.60) (72.38) +3,479.7 pt
Net income (44) (61) (74) (56) (73) 25 (149) (209) (319) (285) (209) +22.9%
Per share, $
Per share, $ Revenue 0.08 0.10 0.06 0.05 0.04 2.68 0.00 0.00 0.28 1.99 3.22 +42.3%
Earnings (3.22) (2.90) (2.92) (1.84) (1.87) 0.48 (2.46) (2.98) (3.72) (3.29) (2.36) +0.2%
Cash flow (2.40) (2.26) (2.70) (1.66) (1.73) 0.56 (2.20) (2.28) (3.21) (3.73) (1.98) +5.0%
Capex (0.02) 0.00 (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (20.8%)
Free cash flow (2.42) (2.26) (2.71) (1.66) (1.73) 0.56 (2.20) (2.28) (3.21) (3.73) (1.98) +4.9%
Book value 5.76 4.97 2.09 1.04 6.11 7.84 7.69 7.88 3.37 0.75 (0.19) (20.3%)
Shares, m 15 21 25 30 41 52 61 70 86 87 88 +21.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 50.91 — — 0.00 0.00 0.00 6.4
P/S 87.72 87.35 74.43 176.47 605.60 8.16 — — 7.53 10.56 2.96 132.2
P/B 1.27 1.77 2.13 8.47 3.64 2.79 — — 3.93 28.16 0.00 6.5
EV/Sales 12.63 32.23 30.17 137.66 425.60 5.10 — — 5.94 10.29 3.56 82.5
EV/FCF (0.43) (1.43) (0.67) (4.11) (9.04) (7.31) — — (2.03) (5.49) (5.80) (3.8)
Cash, $m
Cash, $m Operating cash flow (35) (47) (69) (51) (71) 29 (134) (161) (275) (323) (177) +27.9%
Capex 0 0 0 — — 0 0 — — 0 0 (3.6%)
Free cash flow (35) (47) (69) (51) (71) 29 (133) (161) (275) (323) (178) +27.8%
Balance, $m
Balance, $m Working capital 98 118 67 44 280 428 461 523 500 408 446 +17.2%
Net debt (105) (130) (81) (59) (273) (427) (484) (578) (239) (70) 151 (4.5%)
Shareholders’ equity 84 104 53 32 252 408 467 554 288 65 (17) (2.9%)
Returns, %
Returns, % ROA (47.33) (49.39) (66.90) (76.02) (42.33) 6.64 (31.54) (37.72) (47.66) (45.50) (33.67) +1.8 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (434.21) 0.00 (83.42) 0.0 pt
ROE 53.64 (64.53) (94.00) (132.43) (54.31) 7.55 (34.10) (40.98) (75.69) (161.82) (426.43) (215.5) pt
People
People Employees 33 44 38 35 43 59 107 184 270 298 — +27.7%
Revenue/emp, $m 0.04 0.05 0.04 0.04 0.04 2.37 0.00 0.00 0.09 0.58 — +35.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Syndax Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PHAR Pharming Group N.V. Sponsored ADR $870.6M 34.2× — (loss-making) +20.86% (above 0%: growing) +190.91% (above 0%: growing) +0.42% (above 0%: growing) 86.90% 25.34% Compare
IVA Inventiva S.A. Sponsored ADR $867.9M — (loss-making) — (loss-making) −10.77% (below 0%: shrinking) n/m −20,989.22% (below 0%: shrinking) 0.00% 0.00% Compare
LTGO Latigo Biotherapeutics Inc $862.6M — — — n/m — — 0.00% Compare
ANRO Alto Neuroscience, Inc. $858.2M — (loss-making) — — n/m −43.41% (below 0%: shrinking) — 0.00% Compare
RIGL Rigel Pharmaceuticals, Inc. $853.9M 2.4× 16.4× +16.45% (above 0%: growing) −54.84% (below 0%: shrinking) +43.90% (above 0%: growing) 86.67% 21.15% Compare
SNDX Syndax Pharmaceuticals, Inc. $843.6M — (loss-making) — (loss-making) +81.59% (above 0%: growing) n/m +61.43% (above 0%: growing) 83.20% (50.30%)
AKTS Aktis Oncology, Inc. $826.0M — (loss-making) — (loss-making) — n/m −12.77% (below 0%: shrinking) 100.00% (853.99%) Compare
CRVS Corvus Pharmaceuticals, Inc. $818.5M — (loss-making) — — n/m −171.31% (below 0%: shrinking) 0.00% 0.00% Compare
MGTX MeiraGTx Holdings PLC $817.3M 11.8× 30.3× +8,608.59% (above 0%: growing) n/m +13.06% (above 0%: growing) 97.77% 76.04% Compare
Median of peers $856.0M 11.8× — +18.66% — −12.77% 86.79% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 4.80%
Entities affiliated with Kynam Capital Management LP 9.60%
Entities affiliated with BlackRock, Inc. 7.60%
The Goldman Sachs Group 6.30%
State Street Corporation 5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Syndax Pharmaceuticals, Inc. (SNDX) Latest News

5 Nov

Impact 3 · · GuruFocus.com

3 Nov

Impact 4 · · Moby transcript
Impact 3 · · Simply Wall St.

2 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · GlobeNewswire

28 Oct

Impact 3 · · Zacks

26 Oct

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

15 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 4 · · Zacks
Impact 3 · · biopharmadive.com

13 Oct

Impact 3 · · Simply Wall St.

12 Oct

Impact 4 · · Stocktwits
Impact 3 · · Investing.com
Impact 3 · · GlobeNewswire

22 Aug

Impact 4 ·

12 Aug

Impact 3 ·

11 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 ·

5 Aug

Impact 4 · transcript

4 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

14 Jul

Impact 4 · · MarketBeat
Impact 4 ·
Impact 3 ·

30 Jun

Impact 3 ·

13 Jun

Impact 4 ·

11 Jun

Impact 4 ·
stockrow.com/SNDX · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com